The revenue for ATA-3219 is expected to reach an annual total of $70 mn by 2038 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
ATA-3219 Overview
ATA-3219 is under development for the treatment of relapsed/refractory B-Cell non-Hodgkin lymphoma, diffuse large b-cell lymphoma, follicular lymphoma, mantle cell lymphoma, autoimmune diseases including systemic lupus erythematosus, multiple sclerosis and lupus nephritis. The drug candidate acts by targeting CD19. It comprise of genetically engineered allogeneic chimeric antigen receptor-modified T cells and is developed based on the Epstein Barr virus (EBV) T-cell platform. It is developed based on 1XX co-stimulation technology. It is administered through intravenous route.
Atara Biotherapeutics Overview
Atara Biotherapeutics (Atara) is a biotechnology company that specializes in T-cell immunotherapy, focusing on its innovative allogeneic Epstein-Barr virus (EBV) T-cell platform for developing therapies for patients with cancer and autoimmune disease. Its product pipeline includes tab-cel (Ebvallo) for the treatment of EBV+ post-transplant lymphoproliferative disease (EBV+ PTLD) and ATA3219, an allogeneic CAR T therapy targeting CD19. The company’s preclinical programs include ATA3431 for dual CD19/CD20 targeting in B-cell malignancies, ATA188 for EBV in multiple sclerosis, and an innovative EBV vaccine research. Atara is headquartered in Thousand Oaks, California, the US.
The company reported revenues of (US Dollars) US$8.6 million for the fiscal year ended December 2023 (FY2023), a decrease of 86.5% over FY2022. The operating loss of the company was US$276 million in FY2023, compared to an operating loss of US$280.5 million in FY2022. The net loss of the company was US$276.1 million in FY2023, compared to a net loss of US$228.3 million in FY2022. The company reported revenues of US$28.6 million for the second quarter ended June 2024, an increase of 4.7% over the previous quarter.
For a complete picture of ATA-3219’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.
Sign up for our daily news round-up!
Give your business an edge with our leading industry insights.
From 
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.
The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.